Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.22 is 163% above its 5-year average of 3.51, near the high end of its 5-year range (0.34–11.45).
As of the fiscal period ended Tuesday, June 30, 2026. 11.11% above its 12-month average of 8.30.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.22.
QUICK RATIO (ACID-TEST)
9.22
QUICK RATIO (ACID-TEST) AVG TTM
8.30
QUICK RATIO (ACID-TEST) AVG 3Y
5.18
QUICK RATIO (ACID-TEST) AVG 5Y
3.51
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.11%
CURRENT VS 3Y AVG
+77.98%
CURRENT VS 5Y AVG
+162.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 792 covered companies
CURRENT VS SECTOR MEDIAN
+181.14%
vs the sector median at left
SAB Biotherapeutics, Inc.
Market Cap
$276.14M
Quick Ratio (Acid-Test)
9.22
TTM Avg
8.30
3Y Avg
5.18
5Y Avg
3.51
Market Cap
$280.29M
Quick Ratio (Acid-Test)
2.80
TTM Avg
2.74
3Y Avg
2.22
5Y Avg
2.48
Market Cap
$273.33M
Quick Ratio (Acid-Test)
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
Market Cap
$271.90M
Quick Ratio (Acid-Test)
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$282.68M
Quick Ratio (Acid-Test)
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.05
Market Cap
$283.87M
Quick Ratio (Acid-Test)
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$269.92M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.83M
Quick Ratio (Acid-Test)
6.40
TTM Avg
6.41
3Y Avg
5.95
5Y Avg
4.92
Market Cap
$286.50M
Quick Ratio (Acid-Test)
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $276.14M | 9.22 | 8.30 | 5.18 | 3.51 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | 2.80 | 2.74 | 2.22 | 2.48 |
| Fate Therapeutics, Inc. (FATE)vs › | $273.33M | 4.85 | 6.69 | 6.56 | 6.64 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.90M | 9.24 | 7.84 | 8.19 | 10.90 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | 31.35 | 25.02 | 20.04 | 16.05 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.87M | 4.69 | 11.27 | 11.27 | 11.27 |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.92M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | 6.40 | 6.41 | 5.95 | 4.92 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $286.50M | 19.48 | 1.73 | 4.11 | 4.35 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | 4.46 | 8.30 | 6.73 | 6.78 |
Quick Ratio
9.22
Excludes inventory
Current Ratio
9.22
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.22 |
| 2026-03-31 | 11.45 |
| 2025-12-31 | 9.46 |
| 2025-09-30 | 10.50 |
| 2025-06-30 | 0.87 |
| 2025-03-31 | 1.69 |
| 2024-12-31 | 2.98 |
| 2024-09-30 | 3.69 |
| 2024-06-30 | 5.24 |
| 2024-03-31 | 5.65 |
| 2023-12-31 | 5.45 |
| 2023-09-30 | 0.34 |
| 2023-06-30 | 0.82 |
| 2023-03-31 | 1.10 |
| 2022-12-31 | 1.47 |
| 2022-09-30 | 1.30 |
| 2022-06-30 | 1.72 |
| 2022-03-31 | 1.98 |
| 2021-12-31 | 1.90 |
| 2021-09-30 | 2.09 |
| 2021-06-30 | 2.72 |
| 2021-03-31 | 14.01 |
| 2020-12-31 | 3.11 |
